Huadong Medicine Co., Ltd

000963

CNE0000011S1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 17/01/2025			5-day change	1st Jan Change
32.93 ^CNY	-0.33%		+0.92%	-4.83%

01-12	Ashvattha Therapeutics, Inc. announced that it has received $119 million in funding from Huadong Medicine Co., Ltd, Natural Capital Investment Fund, Inc., Plum Alley Co., Tribe Capital Management, LLC and other investors	CI
01-03	Huadong Medicine Subsidiary Gets Aproval for HDM1005 Weight Management Drug Clinical Trials	MT

Chinese Drug Administration Accepts Supplementary Application of Huadong Medicine's Unit for Psoriasis Drug

December 03, 2024 at 05:33 am

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Huadong Medicine Co., Ltd

Ashvattha Therapeutics, Inc. announced that it has received $119 million in funding from Huadong Medicine Co., Ltd, Natural Capital Investment Fund, Inc., Plum Alley Co., Tribe Capital Management, LLC and other investors	01-12	CI
Huadong Medicine Subsidiary Gets Aproval for HDM1005 Weight Management Drug Clinical Trials	01-03	MT
Hangzhou Sino-US Huadong Medicine Co., Ltd. and SynerK PharmaTech Co., Ltd. Reaches Strategic Cooperation	12-30	CI
Huadong Medicine's Unit Gets Nod to Trial Diabetes Drug in US	12-19	MT
Huadong Medicine's Unit Gets Nod for Rilonacept for Injection's Registration	12-11	MT
Chinese Drug Administration Accepts Supplementary Application of Huadong Medicine's Unit for Psoriasis Drug	12-03	MT
Huadong Medicine's Drugs Included in National Insurance Catalog	12-02	MT
Huadong Medicine Obtains Drug Registration for Somituximab Injection	11-28	MT
Huadong Medicine Gets US FDA Approval to Conduct Clinical Trials for HDM1005 Injection	11-19	MT
Huadong Medicine Unit Gets Approval to Conduct Clinical Trials for DR10624 Injection	11-19	MT
Huadong Medicine Gets Drug Registration for Plaque Psoriasis Treatment Drug; Shares Up 3%	11-06	MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024	24/10/24	CI
Huadong Medicine Gets Nod to Trial HDP-101 Drug	16/10/24	MT
Huadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials	11/10/24	MT
Huadong Medicine Gets Clinical Trial Approvals for Two Skin Cream Variants	30/09/24	MT
Huadong Medicine Gets China Device Approval for Radio Frequency Skin Treatment Device	25/09/24	MT
Huadong Medicine Ends Research on Weight Loss Drug; Shares Jump 5%	16/08/24	MT
Huadong Medicine Secures License For IMBiologics' Autoimmune Drugs	16/08/24	MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	15/08/24	CI
Huadong Medicine Buys Rights of ImmunoPharma Technology's Drug for Leukemia, Lymphoma	05/08/24	MT
Qyuns Therapeutics Enters Development, Potential Commercialization Partnership for QX005N	22/07/24	MT
Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug	22/07/24	MT
Huadong Medicine Buys Acute Ischemic Stroke Drug's Rights for 1.19 Billion Yuan	15/07/24	MT
Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug	02/07/24	MT
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China	25/06/24	DJ

Chart Huadong Medicine Co., Ltd

Duration

Period

000963: Dynamic Chart

Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.

Employees

16,969

Sector

Pharmaceuticals

Calendar

16/04/2025 - Q4 2024 Earnings Release (Projected)

More about the company